BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $19.6364.

Several equities research analysts have recently weighed in on the company. Evercore started coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright lifted their target price on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Finally, Royal Bank Of Canada decreased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider directly owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in BCRX. Larson Financial Group LLC lifted its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth purchased a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $77,000. Farther Finance Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the period. Finally, Vestmark Advisory Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.80 on Tuesday. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The company has a market capitalization of $2.46 billion, a P/E ratio of 8.17 and a beta of 0.73. The stock has a 50-day simple moving average of $7.55 and a 200-day simple moving average of $7.44.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $1.05. The firm had revenue of $163.28 million for the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The firm’s quarterly revenue was up 209.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.13) EPS. As a group, analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.